Defective DNA Mismatch Repair-dependent c-Abl-p73-GADD45α Expression Confers Cancer Chemoresistance

Long Shan Li, Mark Wagner, Mark Meyers, David A. Boothman

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

This chapter discusses the defective DNA mismatch repair (MRR). DNA mismatch repair (MMR) is a highly conserved repair pathway that plays an important role in the detection and correction of errors created during/after DNA replication (i.e., post-replication repair) and/or after natural genetic recombination events. Genes encoding homologs of bacterial MutS and MutL have been identified in a variety of eukaryotic model systems, including yeast, plants, insects, nematodes, and mammals. In contrast, MMR-deficient cells ignore these DNA lesions, leading to chemoresistance and damage tolerance to O6-meG DNA lesions generated by specific alkylating agents, such as Temozolomide (TMZ). The net effect is the emergence of drug-resistant, highly mutagenic cell populations that progress rapidly to kill the patient. Potential strategies to overcome MMR-deficient mediated chemoresistance based on accumulated evidence were discussed and included the use of agents, such as FdCyd, that can simultaneously hypomethylate an epigenetically silenced hMLH1 promoter resulting in hMLH1 re-expression, and sensitize the emerging cells that have restored MMR capacity.

Original languageEnglish (US)
Title of host publicationDNA Repair in Cancer Therapy
PublisherElsevier Inc.
Pages191-210
Number of pages20
ISBN (Print)9780123849991
DOIs
StatePublished - 2012

Fingerprint

DNA Mismatch Repair
temozolomide
Neoplasms
Alkylating Agents
DNA
DNA Replication
Genetic Recombination
Insects
Mammals
Yeasts
Pharmaceutical Preparations
Population
Genes

ASJC Scopus subject areas

  • Dentistry(all)
  • Medicine(all)

Cite this

Li, L. S., Wagner, M., Meyers, M., & Boothman, D. A. (2012). Defective DNA Mismatch Repair-dependent c-Abl-p73-GADD45α Expression Confers Cancer Chemoresistance. In DNA Repair in Cancer Therapy (pp. 191-210). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-384999-1.10009-5

Defective DNA Mismatch Repair-dependent c-Abl-p73-GADD45α Expression Confers Cancer Chemoresistance. / Li, Long Shan; Wagner, Mark; Meyers, Mark; Boothman, David A.

DNA Repair in Cancer Therapy. Elsevier Inc., 2012. p. 191-210.

Research output: Chapter in Book/Report/Conference proceedingChapter

Li, LS, Wagner, M, Meyers, M & Boothman, DA 2012, Defective DNA Mismatch Repair-dependent c-Abl-p73-GADD45α Expression Confers Cancer Chemoresistance. in DNA Repair in Cancer Therapy. Elsevier Inc., pp. 191-210. https://doi.org/10.1016/B978-0-12-384999-1.10009-5
Li, Long Shan ; Wagner, Mark ; Meyers, Mark ; Boothman, David A. / Defective DNA Mismatch Repair-dependent c-Abl-p73-GADD45α Expression Confers Cancer Chemoresistance. DNA Repair in Cancer Therapy. Elsevier Inc., 2012. pp. 191-210
@inbook{402c40e36df844b0b561084aa79153a9,
title = "Defective DNA Mismatch Repair-dependent c-Abl-p73-GADD45α Expression Confers Cancer Chemoresistance",
abstract = "This chapter discusses the defective DNA mismatch repair (MRR). DNA mismatch repair (MMR) is a highly conserved repair pathway that plays an important role in the detection and correction of errors created during/after DNA replication (i.e., post-replication repair) and/or after natural genetic recombination events. Genes encoding homologs of bacterial MutS and MutL have been identified in a variety of eukaryotic model systems, including yeast, plants, insects, nematodes, and mammals. In contrast, MMR-deficient cells ignore these DNA lesions, leading to chemoresistance and damage tolerance to O6-meG DNA lesions generated by specific alkylating agents, such as Temozolomide (TMZ). The net effect is the emergence of drug-resistant, highly mutagenic cell populations that progress rapidly to kill the patient. Potential strategies to overcome MMR-deficient mediated chemoresistance based on accumulated evidence were discussed and included the use of agents, such as FdCyd, that can simultaneously hypomethylate an epigenetically silenced hMLH1 promoter resulting in hMLH1 re-expression, and sensitize the emerging cells that have restored MMR capacity.",
author = "Li, {Long Shan} and Mark Wagner and Mark Meyers and Boothman, {David A.}",
year = "2012",
doi = "10.1016/B978-0-12-384999-1.10009-5",
language = "English (US)",
isbn = "9780123849991",
pages = "191--210",
booktitle = "DNA Repair in Cancer Therapy",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Defective DNA Mismatch Repair-dependent c-Abl-p73-GADD45α Expression Confers Cancer Chemoresistance

AU - Li, Long Shan

AU - Wagner, Mark

AU - Meyers, Mark

AU - Boothman, David A.

PY - 2012

Y1 - 2012

N2 - This chapter discusses the defective DNA mismatch repair (MRR). DNA mismatch repair (MMR) is a highly conserved repair pathway that plays an important role in the detection and correction of errors created during/after DNA replication (i.e., post-replication repair) and/or after natural genetic recombination events. Genes encoding homologs of bacterial MutS and MutL have been identified in a variety of eukaryotic model systems, including yeast, plants, insects, nematodes, and mammals. In contrast, MMR-deficient cells ignore these DNA lesions, leading to chemoresistance and damage tolerance to O6-meG DNA lesions generated by specific alkylating agents, such as Temozolomide (TMZ). The net effect is the emergence of drug-resistant, highly mutagenic cell populations that progress rapidly to kill the patient. Potential strategies to overcome MMR-deficient mediated chemoresistance based on accumulated evidence were discussed and included the use of agents, such as FdCyd, that can simultaneously hypomethylate an epigenetically silenced hMLH1 promoter resulting in hMLH1 re-expression, and sensitize the emerging cells that have restored MMR capacity.

AB - This chapter discusses the defective DNA mismatch repair (MRR). DNA mismatch repair (MMR) is a highly conserved repair pathway that plays an important role in the detection and correction of errors created during/after DNA replication (i.e., post-replication repair) and/or after natural genetic recombination events. Genes encoding homologs of bacterial MutS and MutL have been identified in a variety of eukaryotic model systems, including yeast, plants, insects, nematodes, and mammals. In contrast, MMR-deficient cells ignore these DNA lesions, leading to chemoresistance and damage tolerance to O6-meG DNA lesions generated by specific alkylating agents, such as Temozolomide (TMZ). The net effect is the emergence of drug-resistant, highly mutagenic cell populations that progress rapidly to kill the patient. Potential strategies to overcome MMR-deficient mediated chemoresistance based on accumulated evidence were discussed and included the use of agents, such as FdCyd, that can simultaneously hypomethylate an epigenetically silenced hMLH1 promoter resulting in hMLH1 re-expression, and sensitize the emerging cells that have restored MMR capacity.

UR - http://www.scopus.com/inward/record.url?scp=84882395189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882395189&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-384999-1.10009-5

DO - 10.1016/B978-0-12-384999-1.10009-5

M3 - Chapter

AN - SCOPUS:84882395189

SN - 9780123849991

SP - 191

EP - 210

BT - DNA Repair in Cancer Therapy

PB - Elsevier Inc.

ER -